Amyloidosis Foundation

amyloidosis.org · American English

rss2 wordpress content atom dc sy

Open the feed

https://amyloidosis.org/feed/

Last post: Sep 8, 2026
Posts in 24 h · 7 days · 30 days: 0 · 0 · 1
Our last check: Answering
Served from: United States
Site title: Home
Text score at discovery: 1,800
Format: rss2
Features in the feed: content, atom, dc, sy
Community: wordpress

Posts

What our queue read from this feed. Open one to read it here, or go to the site that published it.

Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis
Sep 8, 2026 · original
August 12, 2026 NAPLES, Fla., August 12, 2026 — Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for zamubafusp alfa (AT-02) for the treatment of light chain (AL)-associated amyloidosis, a rare, progressive, debilitating, and often fatal condition. Zamubafusp alfa, the company’s lead pan-amyloid removal candidate, has been evaluated in a completed Phase 1 study and an ongoing Phase 2 open-label trial, both of which have enrolled patients with AL amyloidosis. The granting of Fast Track designation indicates that clinical data from the Phase 1 / 2 program demonstrate that zamubafusp alfa has the potential to address an important unmet medical need in AL amyloidosis. “We are pleased to ha
2026 Summer Newsletter
Jul 30, 2026 · original
Our latest Summer Newsletter is here! Catch up on the latest Amyloidosis Foundation news, upcoming events, and ways you can get involved. We hope you’ll take a few minutes to check it out and stay connected with everything happening this summer! Click HERE to read the newsletter.
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
Jul 23, 2026 · original
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – No relapses to-date observed for patients who have reached CR – – All subsequently enrolled patients for whom MRD results are available are MRD-negative at one month – – Next NEXICART-2 Update Expected Late September, 2026 – LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced that all four relapsed/refractory AL Amyloidosis MRD-negative patients presented at ASH 2025 have converted to complete response (CR). The NEXICART-2 CR rate is now 95% (19 out of 20 patients). All CRs were reached within 1 year of follow-up post-dosing. No relapses have been observed as of today for patient
Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis
Jun 16, 2026 · original
NAPLES, Fla., June 4, 2026— Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for zamubafusp alfa (AT-02) for the treatment of light chain (AL) amyloidosis, a rare, progressive, debilitating, and often fatal condition. Zamubafusp alfa, the company’s lead pan-amyloid removal candidate, has been evaluated in a completed Phase 1 study and is currently being studied in an ongoing Phase 2 open-label trial, both of which enrolled patients with AL amyloidosis. “We are pleased to have received orphan drug designation from the U.S. FDA for zamubafusp alfa in AL amyloidosis,” said Gregory Bell, M.D., Chief Medical Officer at Attralus. “Current approved therapies for AL target light-chain product
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
Jun 16, 2026 · original
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – No relapses to-date observed for patients who have reached CR – – All subsequently enrolled patients for whom MRD results are available are MRD-negative at one month – – Next NEXICART-2 Update Expected Late September, 2026 – L OS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced that all four relapsed/refractory AL Amyloidosis MRD-negative patients presented at ASH 2025 have converted to complete response (CR). The NEXICART-2 CR rate is now 95% (19 out of 20 patients). All CRs were reached within 1 year of follow-up post-dosing. No relapses have been observed as of today for patien
CARES Phase III clinical program did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosis
May 29, 2026 · original
PUBLISHED 29 May 2026 AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on Social Media @AstraZeneca . Anselamimab demonstrated 62% improvement in survival and 71% reduction in cardiovascular hospitalizations in prespecified kappa light-chain amyloidosis subgroup Results published in the Journal of Clinical Oncology and will be presented at 2026 American Society of Clinical Oncology Annual Meeting The global CARES Phase III clinical program showed th
2026 Spring Newsletter
Apr 30, 2026 · original
Be sure to catch up on the latest happenings in our spring newsletter here !
2026 Winter Newsletter
Jan 15, 2026 · original
Be sure to catch up on the latest happenings in our winter newsletter here !
Light the Night for Amyloidosis March 2026: Shining a Beacon of Awareness and Hope
Jan 6, 2026 · original
Each year, landmarks, homes, and communities across the country light up in red to honor those affected by amyloidosis and to raise awareness of this rare disease. Light the Night for Amyloidosis is a simple but powerful way to spark conversation, encourage earlier diagnosis, and show solidarity with patients, caregivers, families, and clinicians who are part of our community. We invite supporters everywhere to participate—whether that means illuminating your porch light, asking a local building or bridge to light up, or sharing photos on social media to spread the word. Every light symbolizes hope and helps amplify the message that awareness saves lives. To make participation easier, the Amyloidosis Foundation has created a Light the Night for Amyloidosis outreach toolkit. This free toolkit includes: Sample request letters and emails you can send to city halls, landmarks, and organizati
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid CardiomyopathyResults From ATTRibute-CM and Its Open-Label Extension
Nov 12, 2025 · original
JAMA Cardiol Published Online: November 8, 2025 Today at the AHA congress in New Orleans, BridgeBio presented data showing that acoramidis significantly reduces all-cause mortality (through month 42) in people living with hereditary ATTR-CM population, with specific benefit noted in those living with the V122i variant. These data have also been published today in JAMA Cardiology . You can read more information about this in our press release: https://bit.ly/4nKaCRz

Discovered by the rss-feed-index crawler, which checks each feed at most once a month.

Same record as JSON: https://api.agentalog.com/api/feeds/fd_amyloidosis_org_91109f73ff1ef243. More from this site: amyloidosis.org in the Feeds tab.